RESUMEN
Introduction: Data on the relationship between Coronavirus disease-2019 (COVID-19) and acute pancreatitis are limited. This study aimed to investigate the possible role of COVID-19 in the etiology of acute pancreatitis in a tertiary-care educational university hospital by retrospectively evaluating the incidence of acute pancreatitis in adult hospitalized patients with COVID-19. Materials and Methods: Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR)-positive adult inpatients from March 15, 2020, to February 1, 2021, constituted the study group in our hospital. This cohort was analyzed for acute pancreatitis criteria, including acute abdominal pain, increased amylase and/or lipase more than three times the normal value, and radiological finding supporting the disease. Patients who met at least two of the acute pancreatitis diagnostic criteria were determined, and those who met the criteria during or after SARS-CoV-2 PCR positivity detection were included in the study. These patients were further analyzed for COVID-19-related data and pancreatitis severity status. Results: Our hospital had 1227 inpatients with COVID-19 diagnosis in one year. A total of four cases met the inclusion criteria. Acute pancreatitis rates were detected at 0.3% and 1.07% for all cohorts (n=1227) and the pancreatic enzyme-tested group (n=372), respectively. Of these four patients, two (50%) were females (50%) and the mean age was 70.7 (range: 64-79) years. There was no correlation between COVID-19 pneumonia and pancreatitis severity scores, including Ranson, Acute Physiologic Assessment and Chronic Health Evaluation 2, and modified computed tomography severity scores. Conclusion: COVID-19 is a rare risk factor for acute pancreatitis and did not affect the pancreatitis severity or mortality in our cohort.
RESUMEN
Introduction: There are similarities in the pathogenesis of COVID-19 and autoimmune diseases. In addition, due to the molecular similarities between the antigens of the virus and the antigenic structures in the human body, autoimmune diseases such as arthritis may occur or exacerbate after COVID-19 vaccines. In this publication, a retrospective evaluation of the patients who applied to the Rheumatology Outpatient Clinic with arthritis and other autoimmune complaints that developed or exacerbated after the COVID-19 vaccine was performed. Materials and Methods: Patients who applied to the Rheumatology outpatient clinics of our hospital were screened retrospectively, and patients who presented with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination were determined. The files of these patients were reviewed retrospectively. Demographic characteristics of the patients, history of rheumatological disease, COVID-19 vaccinations, mean time to symptom development after vaccination, localization of arthritis, laboratory findings, imaging findings, treatment and treatment response were evaluated. Results: There are seven patients who applied to Rheumatology clinics with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination in the last year. Three patients (no previous history of rheumatological disease) had newly emerged inflammatory arthritis, one stable gout, and one Sjogrens syndrome patient had exacerbated arthritis and two dermatomyositis cases (one newly diagnosed and the other exacerbation). Conclusion: The benefits of the vaccines are greater than the side effects that may develop, and vaccination should be continued in line with the recommendations. Although the temporal connection between the appearance of symptoms and the vaccination procedure in our study supports the relationship with the COVID-19 vaccine, it should never be forgotten that vaccines are the most effective way to prevent the disease.
RESUMEN
Introduction: There are similarities in the pathogenesis of COVID-19 and autoimmune diseases. In addition, due to the molecular similarities between the antigens of the virus and the antigenic structures in the human body, autoimmune diseases such as arthritis may occur or exacerbate after COVID-19 vaccines. In this publication, a retrospective evaluation of the patients who applied to the Rheumatology Outpatient Clinic with arthritis and other autoimmune complaints that developed or exacerbated after the COVID-19 vaccine was performed. Material(s) and Method(s): Patients who applied to the Rheumatology outpatient clinics of our hospital were screened retrospectively, and patients who presented with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination were determined. The files of these patients were reviewed retrospectively. Demographic characteristics of the patients, history of rheumatological disease, COVID-19 vaccinations, mean time to symptom development after vaccination, localization of arthritis, laboratory findings, imaging findings, treatment and treatment response were evaluated. Result(s): There are seven patients who applied to Rheumatology clinics with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination in the last year. Three patients (no previous history of rheumatological disease) had newly emerged inflammatory arthritis, one stable gout, and one Sjogrens syndrome patient had exacerbated arthritis and two dermatomyositis cases (one newly diagnosed and the other exacerbation). Conclusion(s): The benefits of the vaccines are greater than the side effects that may develop, and vaccination should be continued in line with the recommendations. Although the temporal connection between the appearance of symptoms and the vaccination procedure in our study supports the relationship with the COVID-19 vaccine, it should never be forgotten that vaccines are the most effective way to prevent the disease.Copyright © 2022 Bilimsel Tip Yayinevi. All rights reserved.
RESUMEN
Introduction: There are similarities in the pathogenesis of COVID-19 and autoimmune diseases. In addition, due to the molecular similarities between the antigens of the virus and the antigenic structures in the human body, autoimmune diseases such as arthritis may occur or exacerbate after COVID-19 vaccines. In this publication, a retrospective evaluation of the patients who applied to the Rheumatology Outpatient Clinic with arthritis and other autoimmune complaints that developed or exacerbated after the COVID-19 vaccine was performed. Materials and Methods: Patients who applied to the Rheumatology outpatient clinics of our hospital were screened retrospectively, and patients who presented with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination were determined. The files of these patients were reviewed retrospectively. Demographic characteristics of the patients, history of rheumatological disease, COVID-19 vaccinations, mean time to symptom development after vaccination, localization of arthritis, laboratory findings, imaging findings, treatment and treatment response were evaluated. Results: There are seven patients who applied to Rheumatology clinics with newly developed or exacerbated autoimmune complaints after COVID-19 vaccination in the last year. Three patients (no previous history of rheumatological disease) had newly emerged inflammatory arthritis, one stable gout, and one Sjögrens syndrome patient had exacerbated arthritis and two dermatomyositis cases (one newly diagnosed and the other exacerbation). Conclusion: The benefits of the vaccines are greater than the side effects that may develop, and vaccination should be continued in line with the recommendations. Although the temporal connection between the appearance of symptoms and the vaccination procedure in our study supports the relationship with the COVID-19 vaccine, it should never be forgotten that vaccines are the most effective way to prevent the disease.
RESUMEN
Introduction: The new coronavirus named SARS-CoV-2, emerged in Wuhan, China in December 2019 and caused a pandemic. Unusual clinic of viral pneumonia caused by this virus was named COVID-19 and pandemic was declared on 11 March 2020 by World Health Organization. In this study, it was aimed to investigate the epidemiological and clinical characteristics of pediatric and adult patients who were admitted to Ege University Faculty of Medicine (EUFM) Hospital, Izmir, Turkey with COVID-19 findings between March 2020 and February 2021 and whose diagnosis was confirmed by the SARS-CoV-2 RT-PCR test. Materials and Methods: Age and gender characteristics of the patients were screened according to the services and months they admitted to the hospital, and the severity of infection was evaluated in three groups as mild, moderate and severe. In the severe patient group, the relationship between the common comorbid diseases observed in the community and survival status of patients were also evaluated. All statistical analysis performed by SPSS V.26,0. Results: One year from the start of the pandemic, 75851 people applied to the EUFM Hospital with the suspicion of COVID-19. The age median of the patients who applied was 39 (age-range;0-96) and 50.7% were male patients. SARS-CoV-2 were detected in a total of 7951 (10.5%, median age 39) patients, of them 4044 (10.5%) were male and 3907 (10.5%) were female (p= 0.796). All of the patients, 66577 (87.8%) were adults and 9274 (12.2%) were children. The rate of positivity for SARS-CoV2 in pediatric and adult groups were 7.7% (n= 716) and 10.9% (7235), respectively (p= 0.000). The percentage of patients who were classified as mild, moderate, and severe were 92.7%, 3.4%, and 3.9%, respectively. As a result of paired comparisons for all three level case groups, a statistically significant difference was found between mild cases and others (p= 0.000). However, there was no statistically significant difference between moderate and severe cases (p= 0.298). The mild-moderate-severe clinical level distributions were 3721 (50.4%), 142 (52.7%), 181 (58.7%) in male, 3653 (49.5%), 127 (47.2%), 127 (41.2%) in female, respectively (p= 0.014). All severe clinical level patients, 234 (76%) were intensive care patients. Smoking, obesity, hypertension (HT), diabetes mellitus (DM), coronary artery disease (CAD), congestive heart failure (CHF), chronic renal failure (CRF), chronic obstructive pulmonary disease (COPD),malignancy, and chemotherapy p values were found 0.037, 0.001, 0.052, 0.025, 0.003, 0.004, 0.006, 0.558, 0.355, 0.056, respectively. Conclusion: As a result, in a one-year period, COVID-19 showed up a mild illness in both the pediatric and adult groups without the need for hospitalization. In the community, women and men were equally infected with COVID-19, but severe-clinical-level disease was more common in men and over 60 years of age. Mortality rates were found to be high, especially in patients treated in intensive care. Smoking, obesity, DM, CAD, CHF, CRF comorbidities and being ≥60 years old, associated with poor prognosis and death. Due to the Izmir earthquake at the end of October, COVID-19 peaked in Ízmir, in November 2020.